Genfit: net loss widens in 2023
The biopharmaceutical company's revenues rose to 38.2 million euros from 26.6 million in 2022, but its operating expenses increased to 64.8 million due to a 10.7 million increase in R&D costs.
Genfit expects its cash and cash equivalents to be sufficient to finance its operating and capital expenses until approximately the fourth quarter of 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction